Prognostic impact of diabetes mellitus on patients managed by urgent percutaneous coronary intervention

##plugins.themes.academic_pro.article.sidebar##

Published Feb 9, 2022
Download
pdf
Vol. 100 No. 2 (2022): Issue feb 2022

##plugins.themes.academic_pro.article.main##

Anis Ghariani
Hamza Mosrati
Mohamed Aymen Ben
Hatem Bouraoui
Ahmed Fekih Romdhane
Fares Ammar
Abdallah Mahdhaoui
Gouider Jeridi

Abstract

Introduction: Diabetes Mellitus (DM) is known to be associated with worse outcomes following percutaneous coronary intervention (PCI).

Aim: To assess prognostic impact of DM on patients managed by urgent PCI following ST-segment elevation myocardial infarction (STEMI).

Methods: In a retrospective study, STEMI patients admitted to our department from January 2016 to December 2019 and treated with
urgent PCI (primary or rescue PCI) were included. They were divided in two groups: Diabetic and non-diabetic patients. They were
followed-up for a period of 12 months. Major cardiac adverse event (MACE) was a composite outcome of the following events: myocardial
infarction, target vessel revascularization, target lesion revascularization or cardiovascular death. MACEs were collected during follow-up.

Results: Our population consisted of 225 patients. DM was observed in 104 STEMI patients (46.2%). Diabetic patients had higher
frequency of hypertension (p<0.001), low-density lipoprotein cholesterol levels > 1.4mmol/l (p<0.001) and chronic kidney disease (CKD)
(p=0.009). In-hospital and 12-months mortality were significantly higher in the diabetic group (11.5% versus 4.1%; p=0.036) and (24.7%
versus 8.7%; p=0.003). In-hospital and 12-months MACEs were also more frequent among diabetic patients (17.3% versus 6.7%;
p=0.013) and (43.5% versus 17.5%; p<0.001). Main factors associated with in-hospital mortality among diabetic patients were age >
75 years, anemia, CKD, cardiogenic shock and procedural failure. Age > 75 years, hyperglycemia at admission (>10mmol/l), extensive
anterior infarction and procedure failure were associated with in-hospital mortality in the non-diabetic group. Factors associated with
12-months mortality and MACEs among diabetic patients were age > 75 years, anemia, CKD and left ventricular systolic dysfunction.

Conclusions:Despite modern era of STEMI treatment, diabetic patients still have a poor prognosis. These results highlight the need for
coronary risk factors treatment among these patients.

##plugins.themes.academic_pro.article.details##

References

  1. Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH. Modifiable Risk Factors in Young Adults With First Myocardial Infarction. J Am Coll Cardiol. 2019;73:573–84.
  2. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73:629–38.
  3. Foussas SG. Acute coronary syndromes and diabetes mellitus. Hell J Cardiol. 2016;57:375–7.
  4. Barron H V., Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the national registry of myocardial infarction 2. Am Heart J 2001;141:933–9.
  5. Jiang YJ, Han WX, Gao C, Feng J, Chen ZF, Zhang J, et al. Comparison of clinical outcomes after drug-eluting stent implantation in diabetic versus nondiabetic patients in China. Med (United States). 2017;96:1–8.
  6. Chen WW, Chen JY, Li CI, Liu CS, Lin WY, Lin CH, et al. Diabetes mellitus associated with an increased risk of percutaneous coronary intervention long-term adverse outcomes in Taiwan: A nationwide population-based cohort study. J Diabetes Complications. 2020;34:1076–89.
  7. Noman A, Balasubramaniam K, Alhous MHA, Lee K, Jesudason P, Rashid M, et al. Mortality after percutaneous coronary revascularization: Prior cardiovascular risk factor control and improved outcomes in patients with diabetes mellitus. Catheter Cardiovasc Interv. 2017;89:1195–204.
  8. Khalfallah M, Abdelmageed R, Elgendy E, Hafez YM. Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Diabetes Vasc Dis Res. 2020;17:1541–9.
  9. Marfella R, Esposito K, Giunta R. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000;101:2247-52.
  10. Booth G, Stalker TJ, Lefer AM, Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insuline. Am J Physiol Endocrinol Metab. 2001;280:848-56.
  11. Elezi S, Kastrati A, Pache J. Diabetes mellitus and the clinical and the angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866-73.
  12. Capodanno D. Risk stratification for percutaneous coronary intervention. Interv Cardiol Clin 2016;5:249-57.
  13. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haeften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26: 417–22.
  14. Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2009;158:784-5.
  15. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol. 2008;52:1052–59.
  16. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50:1541–7.
  17. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115:708–16.